Focus Equities

Invacare Shares Gain


Invacare shares rose to their highest level since December 2015 on Friday after maker of medical equipment used in non-acute care settings said it expects the US Food and Drug Administration to inspect its corporate and Taylor Street facilities after completing the final two steps required for that to happen. INVA was up 12% recently, trading in a new 52-week range between $8.00 and $16.65.

“In order to progress to the re-inspection, FDA had to receive a third-party expert certification report confirming the company’s substantial compliance with specified FDA regulatory requirements, as well as the company’s own report, as required under paragraph 5(H) of the consent decree, substantiating its compliance,” Invacare said. “Both of these steps have now been completed. Based on the terms of the consent decree, the company expects FDA’s inspection of the impacted facilities to commence within 30 days.”